First National Bank of Hutchinson Buys New Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

First National Bank of Hutchinson acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,563 shares of the company's stock, valued at approximately $786,000.

Other hedge funds have also added to or reduced their stakes in the company. Equitable Trust Co. grew its holdings in shares of Medpace by 133.7% in the 4th quarter. Equitable Trust Co. now owns 2,010 shares of the company's stock valued at $616,000 after acquiring an additional 1,150 shares in the last quarter. Wakefield Asset Management LLLP raised its position in shares of Medpace by 10.8% in the fourth quarter. Wakefield Asset Management LLLP now owns 3,607 shares of the company's stock valued at $1,106,000 after buying an additional 351 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Medpace by 39.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 34,857 shares of the company's stock valued at $10,801,000 after buying an additional 9,896 shares in the last quarter. New York State Teachers Retirement System raised its position in shares of Medpace by 0.3% in the fourth quarter. New York State Teachers Retirement System now owns 33,711 shares of the company's stock valued at $10,333,000 after buying an additional 100 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. raised its position in shares of Medpace by 0.4% in the fourth quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company's stock valued at $3,401,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Up 2.0 %

Shares of NASDAQ MEDP traded up $7.96 during midday trading on Monday, reaching $408.71. 319,486 shares of the company were exchanged, compared to its average volume of 247,893. The stock's 50-day moving average price is $378.34 and its 200-day moving average price is $310.66. The stock has a market cap of $12.66 billion, a P/E ratio of 46.03, a PEG ratio of 2.12 and a beta of 1.38. Medpace Holdings, Inc. has a one year low of $185.43 and a one year high of $419.42.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.22 by $0.24. The firm had revenue of $498.40 million for the quarter, compared to analysts' expectations of $498.72 million. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company's revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.12 earnings per share. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a research report on Saturday, March 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research report on Monday, March 18th. They set a "hold" rating and a $395.00 price objective for the company. Robert W. Baird boosted their price objective on shares of Medpace from $312.00 to $408.00 and gave the company an "outperform" rating in a research report on Wednesday, February 14th. Finally, UBS Group upgraded shares of Medpace from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of "Moderate Buy" and an average target price of $382.00.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 102 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now owns 15,181 shares of the company's stock, valued at $6,117,943. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Medpace news, Director Ashley M. Keating sold 250 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now owns 250 shares of the company's stock, valued at $102,467.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 102 shares of the company's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock valued at $76,651,647 over the last 90 days. 25.70% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.